↓ Skip to main content

Dove Medical Press

Article Metrics

Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis

Overview of attention for article published in Drug Design, Development and Therapy, March 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
34 Mendeley
Title
Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis
Published in
Drug Design, Development and Therapy, March 2016
DOI 10.2147/dddt.s87792
Pubmed ID
Authors

Marco Krasselt, Christoph Baerwald

Abstract

The introduction of modified-release (MR) prednisone adds a drug with encouraging potential to the armamentarium of the rheumatologist. In particular, for patients experiencing a reduced quality of life due to prolonged morning stiffness, it is a promising therapeutic approach. Two clinical trials and one open-label observational study investigated the effectiveness of MR prednisone in reducing rheumatoid arthritis-related morning stiffness for both new and current users of corticosteroids. The efficacy and safety of MR prednisone use in rheumatoid arthritis patients are reviewed in this article. This includes pivotal trials as well as pathophysiological considerations and clinical implications.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 29%
Student > Master 4 12%
Student > Postgraduate 3 9%
Professor 2 6%
Student > Ph. D. Student 2 6%
Other 5 15%
Unknown 8 24%
Readers by discipline Count As %
Medicine and Dentistry 10 29%
Pharmacology, Toxicology and Pharmaceutical Science 5 15%
Biochemistry, Genetics and Molecular Biology 4 12%
Nursing and Health Professions 3 9%
Unspecified 1 3%
Other 3 9%
Unknown 8 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2019.
All research outputs
#12,908,525
of 16,250,537 outputs
Outputs from Drug Design, Development and Therapy
#920
of 1,626 outputs
Outputs of similar age
#188,066
of 268,805 outputs
Outputs of similar age from Drug Design, Development and Therapy
#45
of 83 outputs
Altmetric has tracked 16,250,537 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,626 research outputs from this source. They receive a mean Attention Score of 5.0. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,805 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.